Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 4/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700924 | 0.90 | CYP4F2 (0.46) | CYP4F2CYP4A11TNFCYP1A2SMN1; SMN2 | |
| SCHEMBL5250071 | 0.83 | CYP4F2 (0.48) | CYP4F2CYP4A11TBXAS1CYP1A2CYP4Z1 | |
| SCHEMBL9655979 | 0.81 | MIF (0.44) | SMN1; SMN2LMNAGAA | |
| SCHEMBL2635600 | 0.81 | SMN1; SMN2 (0.51) | CYP1A2SMN1; SMN2LMNACYP3A4MAOA | |
| SCHEMBL17028594 | 0.80 | CYSLTR2 (0.45) | CYP4F2CYP4A11TBXAS1CYP1A2CYP4Z1 | |
| SCHEMBL9657521 | 0.79 | FFAR1 (0.44) | TBXAS1CYSLTR2CYSLTR1 | |
| SCHEMBL3931150 | 0.79 | NPSR1 (0.44) | CYP4F2CYP4A11TBXAS1CYP1A2CYP4Z1 | |
| SCHEMBL13962535 | 0.79 | CYP4F2 (0.43) | CYP4F2CYP4A11TBXAS1CYP1A2CYP4Z1 | |
| SCHEMBL3933040 | 0.79 | FAAH (0.43) | CYP4F2CYP4A11TBXAS1CYP1A2CYP4Z1 | |
| SCHEMBL20201108 | 0.78 | CYP1A2 (0.41) | CYP4F2CYP4A11TNFTBXAS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | CYP4F2 264/4885CYP4A11 131/4885TNF 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.